185 related articles for article (PubMed ID: 3061756)
21. Risk factors for retardation of renal function in IDDM and NIDDM with nephropathy.
Hara S; Arizono K; Ubara Y; Morita T; Suzuki Y; Ogura Y; Hagura R; Akanuma Y
J Diabet Complications; 1991; 5(2-3):131-3. PubMed ID: 1770020
[TBL] [Abstract][Full Text] [Related]
22. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis.
Magee GM; Bilous RW; Cardwell CR; Hunter SJ; Kee F; Fogarty DG
Diabetologia; 2009 Apr; 52(4):691-7. PubMed ID: 19198800
[TBL] [Abstract][Full Text] [Related]
23. The clinical significance of hyperfiltration in diabetes.
Jerums G; Premaratne E; Panagiotopoulos S; MacIsaac RJ
Diabetologia; 2010 Oct; 53(10):2093-104. PubMed ID: 20496053
[TBL] [Abstract][Full Text] [Related]
24. SGLT2 Inhibitors and the Diabetic Kidney.
Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
[TBL] [Abstract][Full Text] [Related]
25. Pathogenesis and course of renal disease in IDDM/NIDDM: differences and similarities.
Ritz E; Keller C; Bergis K; Strojek K
Am J Hypertens; 1997 Sep; 10(9 Pt 2):202S-207S. PubMed ID: 9324123
[TBL] [Abstract][Full Text] [Related]
26. The use of antihypertensive agents in prevention and treatment of diabetic nephropathy.
Parving HH; Rossing P
Curr Opin Nephrol Hypertens; 1994 May; 3(3):292-300. PubMed ID: 7922255
[TBL] [Abstract][Full Text] [Related]
27. Glomerular hyperfiltration in microalbuminuric NIDDM patients.
Vedel P; Obel J; Nielsen FS; Bang LE; Svendsen TL; Pedersen OB; Parving HH
Diabetologia; 1996 Dec; 39(12):1584-9. PubMed ID: 8960846
[TBL] [Abstract][Full Text] [Related]
28. Pathogenesis of diabetic nephropathy.
Raptis AE; Viberti G
Exp Clin Endocrinol Diabetes; 2001; 109 Suppl 2():S424-37. PubMed ID: 11460589
[TBL] [Abstract][Full Text] [Related]
29. Glomerular hyperfiltration in type I, type II, and secondary diabetes.
Marre M; Hallab M; Roy J; Lejeune JJ; Jallet P; Fressinaud P
J Diabetes Complications; 1992; 6(1):19-24. PubMed ID: 1562754
[TBL] [Abstract][Full Text] [Related]
30. Preventing end-stage renal disease.
Mogensen CE
Diabet Med; 1998; 15 Suppl 4():S51-6. PubMed ID: 9868993
[TBL] [Abstract][Full Text] [Related]
31. The stages in diabetic renal disease. With emphasis on the stage of incipient diabetic nephropathy.
Mogensen CE; Christensen CK; Vittinghus E
Diabetes; 1983 May; 32 Suppl 2():64-78. PubMed ID: 6400670
[TBL] [Abstract][Full Text] [Related]
32. Relationships among microalbuminuria, insulin resistance and renal-cardiac complications in insulin dependent and non insulin dependent diabetes.
Nosadini R; Brocco E
Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():1-7. PubMed ID: 9288531
[TBL] [Abstract][Full Text] [Related]
33. The Hyperfiltering Kidney in Diabetes.
Trevisan R; Dodesini AR
Nephron; 2017; 136(4):277-280. PubMed ID: 27978521
[TBL] [Abstract][Full Text] [Related]
34. Differences in susceptibility to develop parameters of diabetic nephropathy in four mouse strains with type 1 diabetes.
Franzén S; Friederich-Persson M; Fasching A; Hansell P; Nangaku M; Palm F
Am J Physiol Renal Physiol; 2014 May; 306(10):F1171-8. PubMed ID: 24623147
[TBL] [Abstract][Full Text] [Related]
35. [Endothelial relaxation factor in the development of diabetic nephropathy].
Shestakova MV; Severina IS; Dedov II; Ragozin AK; Belushkina NN; Riaposova IK
Vestn Ross Akad Med Nauk; 1995; (5):30-4. PubMed ID: 7626982
[TBL] [Abstract][Full Text] [Related]
36. Early glomerular hyperfiltration in insulin-dependent diabetics and late nephropathy.
Mogensen CE
Scand J Clin Lab Invest; 1986 May; 46(3):201-6. PubMed ID: 3715374
[TBL] [Abstract][Full Text] [Related]
37. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade.
Ruggenenti P; Mosconi L; Sangalli F; Casiraghi F; Gambara V; Remuzzi G; Remuzzi A
Kidney Int; 1999 Mar; 55(3):984-94. PubMed ID: 10027935
[TBL] [Abstract][Full Text] [Related]
38. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
Rodby RA; Firth LM; Lewis EJ
Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
[TBL] [Abstract][Full Text] [Related]
39. Diabetic late complications: will aldose reductase inhibitors or inhibitors of advanced glycosylation endproduct formation hold promise?
Boel E; Selmer J; Flodgaard HJ; Jensen T
J Diabetes Complications; 1995; 9(2):104-29. PubMed ID: 7599349
[TBL] [Abstract][Full Text] [Related]
40. Renal hyperfiltration in type 2 diabetes: effect of age-related decline in glomerular filtration rate.
Premaratne E; Macisaac RJ; Tsalamandris C; Panagiotopoulos S; Smith T; Jerums G
Diabetologia; 2005 Dec; 48(12):2486-93. PubMed ID: 16261309
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
